Alternative temozolomide dosing regimens and novel combinations for the treatment of advanced metastatic melanoma

Main Article Content

Wen-Jen Hwu (1*), Ana E. Ayala (2), Ingrid M. Hernandez (3)

1 A.E. Ayala • I.M. Hernandez The University of Texas, MD Anderson Cancer Center, Houston, United States.
2 A.E. Ayala • I.M. Hernandez The University of Texas, MD Anderson Cancer Center, Houston, United States.
3 A.E. Ayala • I.M. Hernandez The University of Texas, MD Anderson Cancer Center, Houston, United States.
(*) Corresponding Author:
Wen-Jen Hwu
wenjhwu@mdanderson.org

Abstract

Over the past 30 years, there has been no significant improvement in treatment outcomes for patients with advanced stage IV metastatic melanoma, and prognosis remains poor. Melanoma is known to be responsive to immunomodulatory agents, to be a highly vascular tumor, and to be fairly resistant to standard cytotoxic chemotherapy. Ongoing research is attempting to find novel combinations that may have therapeutic synergy. Alternative dosedense schedules of temozolomide appear promising and are being actively investigated, based on their potential to overcome chemoresistance to alkylating agents and the proven activity of temozolomide in the brain. Outcomes of studies investigating single-agent temozolomide suggest that it has activity similar to single-agent dacarbazine. Other studies combining temozolomide with either interferon- alfa or thalidomide suggest that the addition of these immunomodulatory agents to temozolomide improves response rates and may improve overall survival. The best results have been achieved with the extended, daily, dosedense temozolomide regimen. Further research is needed to determine the optimal temozolomide regimen and best combination approach

Downloads month by month

Downloads

Download data is not yet available.

Article Details

How to Cite
Hwu, W.-J., Ayala, A. E., & Hernandez, I. M. (2011). Alternative temozolomide dosing regimens and novel combinations for the treatment of advanced metastatic melanoma. Oncology Reviews, 2(3), 183-193. https://doi.org/10.4081/oncol.2008.183